Safety of Repeated Administration of Parenteral Ketamine for Depression

Pharmaceuticals
David FeifelKelly C Lee

Abstract

The objective of this study was to investigate the safety of repeated parenteral ketamine for depression. An electronic survey inquiring about the frequency of adverse events was distributed to providers of parenteral ketamine for depression. In addition, the investigators conducted a search of published studies describing six or more repeated parenteral ketamine treatments administered to individuals for depression, and extracted reported adverse events. The survey was sent to 69 providers, of which 36 responded (52% response rate); after eliminating those that were incomplete, 27 were included in the analysis. The providers in the analysis collectively reported treating 6630 patients with parenteral ketamine for depression, one-third of whom received more than 10 treatments. Only 0.7% of patients experienced an adverse effect that required discontinuation of ketamine. Psychological distress during the treatment was the most frequent cause. Other adverse events were extremely rare (such as bladder dysfunction (0.1%), cognitive decline (0.03%) and psychotic symptoms (0.03%)). Among the 20 published reports of repeated parenteral ketamine treatments, rates of significant adverse events resulting in discontinuation were low (1.2%...Continue Reading

References

Sep 15, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A C LahtiC A Tamminga
May 8, 2007·Urology·Rohan ShahaniRobert J Stewart
Nov 10, 2009·Biological Psychiatry·Marije aan het RotSanjay J Mathew
Jul 23, 2011·Addiction·Celia J A MorganUNKNOWN Independent Scientific Committee on Drugs
Feb 16, 2012·British Medical Bulletin·Eleni Palazidou
Apr 17, 2012·Biological Psychiatry·Pierre BlierJean Blier
Jul 31, 2013·Journal of Clinical Pharmacology·Felix SegmillerCornelius Schüle
Jan 1, 2011·Emerging Health Threats Journal·Sarbjeet S KalsiPaul I Dargan
Jul 21, 2014·Psychopharmacology·Guillaume FondLaurent Boyer
Mar 2, 2016·The American Journal of Psychiatry·Kathryn M SchakMark A Frye
Jun 5, 2016·Brain Research Bulletin·Yu LiuWenhua Zhou
Oct 25, 2016·Journal of Affective Disorders·Jennifer L Vande VoortWilliam V Bobo
Apr 19, 2017·JAMA : the Journal of the American Medical Association·M J Friedrich
May 26, 2017·Therapeutic Advances in Psychopharmacology·Álvaro López-DíazLuis Gutiérrez-Rojas
Jul 4, 2017·The American Journal of Psychiatry·Samuel T WilkinsonGerard Sanacora
Jul 26, 2017·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Duncan GeorgeColleen K Loo
Aug 2, 2017·The Lancet. Psychiatry·Brooke ShortColleen K Loo
Dec 22, 2017·Prehospital and Disaster Medicine·Daniel M BucklandBabak Sarani
Mar 12, 2018·Journal of Affective Disorders·Patricio Riva-PosseWilliam M McDonald
Apr 3, 2018·The American Journal of Psychiatry·Charles B Nemeroff
Jun 19, 2018·Journal of Clinical Psychopharmacology·Shaina ArcherJennifer Swainson
Aug 1, 2018·The Journal of Clinical Psychiatry·Samuel T WilkinsonGerard Sanacora
Aug 11, 2018·Journal of Perinatology : Official Journal of the California Perinatal Association·Megan M GrayTaylor Sawyer
Aug 30, 2018·The American Journal of Psychiatry·Nolan R WilliamsAlan F Schatzberg
Feb 12, 2019·Journal of Clinical Psychopharmacology·Kelly A BryantRoman M Dale
Mar 30, 2019·The American Journal of Psychiatry·Jennifer L PhillipsPierre Blier

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Software Mentioned

Survey Monkey

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

British Journal of Anaesthesia
K Hirota, D G Lambert
JAMA Psychiatry
Christoph KrausSiegfried Kasper
JAMA Psychiatry
Samad E J Golzari, Ata Mahmoodpoor
© 2021 Meta ULC. All rights reserved